A comparison of five common drugudrug interaction software programs regarding accuracy and comprehensiveness

被引:144
作者
Kheshti, Raziyeh [1 ]
Aalipour, Mohammadsadegh [1 ]
Namazi, Soha [1 ]
机构
[1] Shiraz Univ Med Sci, Dept Clin Pharm, Shiraz, Iran
关键词
Accuracy; comprehensiveness; drug interaction screening program; drug-drug interactions software;
D O I
10.4103/2279-042X.192461
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Drugudrug interactions (DDIs) can cause failure in treatment and adverse events. DDIs screening software is an important tool to aid clinicians in the detection and management of DDIs. However, clinicians should be aware of the advantages and limitations of these programs. We compared the ability of five common DDI programs to detect clinically important DDIs. Methods: Lexi-Interact, Micromedex Drug Interactions, iFacts, Medscape, and Epocrates were evaluated. The programs' sensitivity, specificity, and positive and negative predictive values were determined to assess their accuracy in detecting DDIs. The accuracy of each program was identified using 360 unknown pair interactions, taken randomly from prescriptions, and forty pairs of clinically important ones. The major reference was a clinical pharmacist alongside the Stockley's Drug Interaction and databases including PubMed, Scopus, and Google Scholar. Comprehensiveness of each program was determined by the number of components in the drug interaction monograph. The aggregate score for accuracy and comprehensiveness was calculated. Findings: Scoring 250 out of possible 400 points, Lexi-Interact and Epocrates, provided the most accurate software programs. Micromedex, Medscape, and iFacts ranked third, fourth, and fifth, scoring 236, 202, and 191, respectively. In comprehensiveness test, iFacts showed the highest score, 134 out of possible 134 points, whereas Lexi-Interact rated second, with a score of 120. Scoring 370 and 330 out of possible 534 points, Lexi-Interact and Micromedex, respectively, provided the most competent, complete, and user-friendly applications. Conclusion: Lexi-Interact and Micromedex showed the best performances. An increase in sensitivity is possible by the combination of more than one programs and expert pharmacist intervention.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 24 条
  • [1] Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies
    Abarca, J
    Colón, LR
    Wang, VS
    Malone, DC
    Murphy, JE
    Armstrong, EP
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2006, 12 (05): : 383 - 389
  • [2] Evaluation of personal digital assistant software for drug interactions
    Barrons, R
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (04) : 380 - 385
  • [3] Drug interactions in primary care: Impact of a new algorithm on risk determination
    Bergk, V
    Gasse, C
    Rothenbacher, D
    Loew, M
    Brenner, H
    Haefeli, WE
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (01) : 85 - 96
  • [4] Assessment of potential drug-drug interactions at hospital discharge
    Bertoli, R.
    Bissig, M.
    Caronzolo, D.
    Odorico, M.
    Pons, M.
    Bernasconi, E.
    [J]. SWISS MEDICAL WEEKLY, 2010, 140
  • [5] Exposure to potential drug interactions in primary health care
    Bjerrum, L
    Andersen, M
    Petersen, G
    Kragstrup, J
    [J]. SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2003, 21 (03) : 153 - 158
  • [6] Improving recognition of drug interactions - Benefits and barriers to using automated drug alerts
    Glassman, PA
    Simon, B
    Belperio, P
    Lanto, A
    [J]. MEDICAL CARE, 2002, 40 (12) : 1161 - 1171
  • [7] Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study
    Hadjibabaie, Molouk
    Badri, Shirinsadat
    Ataei, Sarah
    Moslehi, Amir Hossein
    Karimzadeh, Iman
    Ghavamzadeh, Ardeshir
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1619 - 1627
  • [8] Preventing drug interactions by online prescription screening in community pharmacies and medical practices
    Halkin, H
    Katzir, I
    Kurman, I
    Jan, J
    Malkin, BBO
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (04) : 260 - 265
  • [9] Hansten P D, 2001, J Am Pharm Assoc (Wash), V41, P161
  • [10] Hazlet T K, 2001, J Am Pharm Assoc (Wash), V41, P200